Factor XIII Val34Leu polymorphism as a modulator of fibrin clot permeability and resistance to lysis in patients with severe coronary artery disease

Kardiologia Polska

Volumn 67, Issue 8, 2009, Pages 947-955

  Stȩpień, Ewa ^a,b   Plicner, Dariusz ^b   Kapelak, Bogusław ^a,b   Wypasek, Ewa ^a,b   Sadowski, Jerzy ^a,b   Undas, Anetta ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Krakowski Szpital Specjalistyczny Im Jana Pawła II   (Poland)

Author keywords

Coronary artery disease; Factor XIII; Fibrinolysis; Polymorphism

Indexed keywords

BLOOD CLOTTING FACTOR 13; C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CROSS LINKING; DEEP VEIN THROMBOSIS; FEMALE; FIBRIN CLOT; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; STATISTICAL ANALYSIS; THROMBOEMBOLISM;

EID: 72449208508     PISSN: 00229032     EISSN: 00229032     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Lorand L. Factor XIII: structure, activation, and interactions with fibrinogen and fibrin. Ann N Y Acad Sci 2001; 936: 291-311. (Pubitemid 32613915)
2. Devine DV, Bishop PD. Platelet-associated factor XIII in platelet activation, adhesion, and clot stabilisation. Semin Thromb Hemost 1996; 22: 409-413
3. Ariens RA, Philippou H, Nagaswami C, et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96: 988-995 (Pubitemid 30616865)
4. Schroeder V, Kohler HP. Effect of factor XIII Val34Leu on α2-antiplasmin incorporation into fibrin. Thromb Haemost 2000; 84: 1128-1130
5. Scott EM, Ariëns RAS, Grant PJ. Genetic and environmental determinants of fibrin structure and function. Relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 1558-1566
6. Lim BC, Ariens RA, Carter AM, et al. Genetic regulation of fibrin structure and function: complex gene-environment interactions may modulate vascular risk. Lancet 2003; 361: 1424-1431
7. Schroeder V, Chatterjee T, Kohler HP. Influence of blood coagulation factor XIII and FXIII Val34Leu on plasma clot formation measured by thromboelastography. Thromb Res 2001; 104: 467-474 (Pubitemid 34086943)
8. Kohler HP, Stickland MH, Ossei-Gerning N, et al. Association of a common polymorphism in the factor XIII gene with myocardial infarction. Thromb Haemost 1998; 79: 8-13. (Pubitemid 28037047)
9. Franco RF, Reitsma PH, Lourenco D, et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81: 676-679 (Pubitemid 29216548)
10. Reiner AP, Schwartz SM, Frank MB, et al. Polymorphisms of coagulation factor XIII subunit A and risk of nonfatal hemorrhagic stroke in young white women. Stroke 2001; 32: 2580-2587
11. Słowik A, Dziedzic T, Pera J, et al. Coagulation factor XIII Val34Leu polymorphism in patients with small vessel disease or primary intracerebral hemorrhage. Cerebrovasc Dis 2005; 19: 165-170 (Pubitemid 40754334)
12. Cushman M, Cornell A, Folsom AR, et al. Associations of the beta-fibrinogen Hae III and factor XIII Val34Leu gene variants with venous thrombosis. Thromb Res 2007; 121: 339-345
13. Shafey M, Anderson JL, Scarvelis D, et al. Factor XIII Val34Leu variant and the risk of myocardial infarction: a meta-analysis. Thromb Haemost 2007; 97: 635-641 (Pubitemid 46592942)
14. Undas A, Sydor WJ, Brummel K, et al. Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 2003; 107: 17-20. (Pubitemid 36070925)
15. Blombäck B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538 (Pubitemid 24267336)
16. Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007; 21: 131-142 (Pubitemid 46541695)
17. Undas A, Brozek J, Jankowski M, et al. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006; 26: 1397-1404 (Pubitemid 44305388)
18. Undas A, Stȩpień E, Szczeklik A. Lipoprotein (a) as a modifier of fibrin clot permability and susceptibility to lysis. J Thromb Haemost 2006; 4: 973-975
19. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 4: 1029-1036
20. Undas A, Plicner D, Stȩpień E, et al. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein (a) and homocysteine. J Thromb Haemost 2007; 5: 1988-1990 (Pubitemid 47288965)
21. Undas A, Szułdrzyński K, Stȩpień E, et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2008; 196: 551-557
22. Williams S, Fatah K, Ivert T, Blombäck M. The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis 1995; 6: 718-725 (Pubitemid 26047201)
23. Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of clot formation, morphology, and lysis. The EuroCLOT Study. Arterioscler Thromb Vasc Biol 2007; 27: 2783-2789
24. Fatah K, Beving H, Albage A, et al. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J 1996; 17: 1362-1366 (Pubitemid 26306664)
25. Undas A, Topor-Madry R, Tracz W. Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn 2009; 119: 354-359
26. Fatah K, Hamsten A, Blombäck B, Blombäck M. Fibrin gel network characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135
27. Fatah K, Silveira A, Tornval P, et al. Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-540 (Pubitemid 26372007)
28. Nair CH, Azhar A, Dhall DP. Studies of fibrin network structure in human plasma. Part One: Methods for clinical application. Thromb Res 1991; 64: 455-476
29. Blomback B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architecture governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538 (Pubitemid 24267336)
30. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol 2005; 27: 81-90.
31. Undas A, Podolec P, Zawilska K, et al. Altered fibrin clot structure/function as a novel risk factor for cryptogenic ischemic stroke. Stroke 2009; 40: 1499-1501
32. Collet JP, Mishal Z, Lesty C, et al. Abnormal fibrin clot architecture in nephritic patients is related to hypofibrinolysis: influence of plasma biochemical modifications. Thromb Haemost 1999; 82: 1482-1489